Industry News
Biotechnology Industry News
Gilead has returned the rights to…
Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was deprioritized earlier this year.
Keros has shaken up its leadership…
Keros has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy asset.
As other pharmas drop next-gen…
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average of 27.3 pounds in the first of two pivotal trials, queuing up plans for a
The Trump administration has…
The Trump administration has broken the law by withholding funds that Congress had allocated to the National Institutes of Health (NIH), according to the Government Accountability Office (GAO).
Alltrna, the preclinical Flagship…
Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic.
Contineum Therapeutics has pumped…
Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.
Kaken Pharmaceutical is paying $16…
Kaken Pharmaceutical is paying $16 million upfront for the Japanese rights to Astria Therapeutics’ phase 3-stage hereditary angioedema drug.
Terns Pharmaceuticals is planning…
Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development at the end of 2025, starting a countdown to potential deals for assets including a midphase oral obesity prospect.
Novo Nordisk has abandoned another…
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that coincides with disappointing obesity sales and a leadership shake-up.
The Department of Health and Human…
The Department of Health and Human Services has announced a plan to end all mRNA vaccine work funded by the Biomedical Advanced Research and Development Authority (BARDA), a major escalation of Secretary Robert F. Kennedy,
As part of a “strategic alignment”…
As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce.
While the ex-Sanofi molecule…
While the ex-Sanofi molecule failed to move the needle in the primary endpoint population, the results in other groups convinced HMNC to start talking to regulators about a phase 3 program.
Imunon has confirmed the…
Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 million in June, management is pushing ahead with plans to find partners for further development of the
Pfizer has jettisoned yet another…
Pfizer has jettisoned yet another GLP-1 drug from its narrowing obesity pipeline, as well as dumping a Clostridium difficile vaccine three years after the candidate failed a phase 3 test.
BioMarin is continuing to slim…
BioMarin is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria drug once touted as a potential successor to its approved med Palynziq.
Vertex Pharmaceuticals has hit a…
Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based big biotech’s sodium channel inhibitor VX-993 failed to outpace placebo at improving pain scores in a
A Senate committee has rejected…
A Senate committee has rejected President Donald Trump’s efforts to gouge funding for the National Institutes of Health (NIH), instead passing draft legislation that would actually increase funding for the nation’s medical research agency by
Praxis Precision Medicines…
Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a quarter of patients discontinuing the
Biotech backer OrbiMed has raised…
Biotech backer OrbiMed has raised $1.86 billion in commitments for its fifth fund aimed at “growth-oriented healthcare companies.”
Xoma Royalty kicked off the week…
Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical setbacks.